C-PBTE-01: Curatis to use US-Zulassung for Krebskandidaten

C-PBTE-01

Curatis will use US-Zulassung for Krebskandidaten

A Biological License Application (BLA) in the US is a big deal for Hoffnungsträger.

Published at 07:52 Uhr

C-PTBE-01 has a group of Behandlung from a group selected by aggressive Hirntumoren.

Photo: Getty Images

Jetzt abonniren und von der useful functions.

Das Biotech-Unternehmen Curatis Holding is an example for Krebskandidaten C-PBTE-01 entschieden of the USA-Zulassung. Donnerstag has a new US Biological License Application (BLA).

Dieser Entscheid has been renamed US-Anwaltskanzlei and has a Prüfung in Zusammenarbeit, with a specialist word on Zulassungs. C-PTBE-01 was accepted as the Criteria for BLA. Herstellung biologist Arzneimittel unterscheidet sich grundlelegend von der Herstellung chemical synthesizer Arzneimittel. This is necessary so that BLA-Zulassungs can be replaced more easily.

It remained longer in the 7 Year Marktschutz in Orphan Drug Status, with C-PTBE-01 becoming a 12-year Marktschutz.

Orphan Drug Status was later compiled with cable C-PTBE-01. In August, Curatis acknowledged this, a condition approved by the FDA. C-PTBE-01 has a group of Behandlung from a group selected by aggressive Hirntumoren.

Another star finds an outdoor air. By once again using cookies containing external Cookies and other contacts, Falls can transfer data to an external Anbiet and directly view and save externally all Cookies.

AWP

Fehler gefunden?Jetzt Melden.

Actien-Warning

ABB bis Züblin – Send an Email, add a new article and find out more.

If you need service, log in or register.

Related Posts